BC Week In Review | Jun 22, 2015
Clinical News

ARGX-111: Phase Ib data

Data from 18 patients with advanced solid tumors overexpressing c-MET in a dose-escalation, Belgian Phase Ib trial showed that the maximum tolerated dose (MTD) of IV ARGX-111 is 3 mg/kg every 3 weeks. The trial...
BC Extra | Jul 9, 2014
Financial News

arGEN-X raises EUR 40 million in Euronext IPO

arGEN-X B.V. (Euronext:ARGX) raised EUR 40 million ($54.6 million) through the sale of 4.7 million shares at EUR 8.50 in an IPO on NYSE Euronext and a private placement to institutional investors. The price --...
BC Extra | Jun 21, 2014
Financial News

arGEN-X sets terms for Euronext IPO

arGEN-X B.V. (Rotterdam, the Netherlands) plans to raise up to EUR 40 million ($54.1 million) through the sale of shares at EUR 8.50-EUR 10.25 in an IPO on NYSE Euronext and a private placement to...
BC Innovations | May 1, 2014
Tools & Techniques

Superhuman mice

The paradox of current mouse-based antibody platforms is that the Ig gene manipulations used to generate the mice can limit the animals' ability to produce robust antibody responses. Kymab Ltd. and Regeneron Pharmaceuticals Inc. have...
BC Week In Review | Sep 23, 2013
Clinical News

ARGX-111: Phase Ib started

arGEN-X began a dose-escalation, Belgian Phase Ib trial to evaluate ARGX-111 in about 35 patients whose tumors overexpress c-Met. The dose-escalation portion will be followed by a safety cohort expansion. arGEN-X B.V. , Rotterdam, the Netherlands...
Items per page:
1 - 5 of 5